ADAPTHEALTH CORP AHCO 深 沪
等待开盘 07-07 09:30:00 美东时间
10.27
-0.490
-4.55%
华盛通- 最 高10.76
- 今 开10.61
- 成交量 120.72万股
- 最 低 10.2228
- 昨 收 10.76
- 总市值 13.97亿
- 52周最高 13.43
- 市盈率 静 --
- 换手率 0.89%
- 52周最低 8.505
- 委 比 -56.73%
- 总股本 1.36亿
- 历史最高 41.579
- 量 比 0.60
- 振 幅 4.99%
- 历史最低 6.37
- 每 手 1
- 风险率 1.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高盛上调AMD目标价从450美元升至640美元；伯恩斯坦上调阿斯麦目标价从1971美元升至2623美元
今日重点评级关注：Roth Capital：维持Nuvectis Pharma"买入"评级，目标价从20美元升至33美元；摩根士丹利：维持GXO Logistics"超配"评级，目标价从75美元升至78美元
今天 11:34
AdaptHealth investigating data breach; shares down 7%
AdaptHealth (ADPT) said some of its computer systems were hit in a cybersecurity attack in the middle of June, adding that the theft of data is "material, due to the nature and potential volume of the...
07-03 04:28
AdaptHealth Discloses Investigation Into Security Incident Where Threat Actor Gained Authorized Access To Systems And Exfiltrated Certain Data; Determined Incident Is Material Due To Nature And Potential Volume; No Material Impact On Operations
AdaptHealth Discloses Investigation Into Security Incident Where Threat Actor Gained Authorized Access To Systems And Exfiltrated Certain Data; Determined Incident Is Material Due To Nature And Potential Volume; No Material Impact On Operations
07-03 04:06
期权扫描 | 业绩再次“炸裂”！美光一巨量Call单或暴赚超550%；纳入指数前夕SpaceX期权交易降温，看涨期权占上风
业绩再次“炸裂”！美光一巨量Call单或暴赚超550%；纳入指数前夕SpaceX期权交易降温，看涨期权占上风；Put单集体飙涨！Strategy期权爆量大增近200%>>
06-25 17:00
AdaptHealth amends 8-K to correct report date for COO appointment
AdaptHealth amends 8-K to correct report date for COO appointment AdaptHealth filed an 8-K/A to correct the report date on its May 5 Form 8-K to May 4, 2026. The amendment also added finalized pay terms for COO Daniel McFadden tied to his May 4 appointment. Base salary rose to $550,000 from $410,000
06-02 18:08
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
UBS Maintains Buy on AdaptHealth, Lowers Price Target to $14
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $15 to $14.
05-07 05:34
AdaptHealth shares are trading lower after the company reorted mixed Q1 financial results.
AdaptHealth shares are trading lower after the company reorted mixed Q1 financi...
05-05 21:21
